Saturday, 31 October 2026
Psychotherapy access income gap, Chronic care cap could rise, Low STI testing in opioid therapy
- 01
Income gap widened in timely access to subsidised psychotherapy
Low-income Australians were substantially less likely to access Medicare-subsidised psychotherapy within three months of receiving a GP mental health treatment plan. Linked tax and Medicare data covering 5.4 million people from 2014–23 showed that, in 2023, 32% of low-income children and 40% of low-income adults accessed psychotherapy within three months, compared with 55% of high-income children and adults. Average real out-of-pocket costs more than doubled over the decade, reaching about $90 per session for children and $80 for adults, while the share of zero-fee services fell sharply. The researchers ruled out changes in mental health disorder complexity and the introduction of telehealth as key drivers of the divide. Lower-income people were also increasingly likely to receive medication without accompanying psychotherapy compared with higher-income people.
via RACGP newsGP
- 02
Draft MBS changes would lift chronic care service cap to 12
Patients could receive 12 subsidised individual chronic condition management services each year, up from five, under draft MBS Review Advisory Committee recommendations. Indigenous patients could access up to 17 services annually, while three time-tiered items would cover appointments of at least 20, 40 or 60 minutes with proportional per-minute benefits. The draft also proposed broader eligibility for group services and expanding the health professionals able to provide them, while leaving GP Chronic Condition Management Plan creation unchanged. About one-third of patients currently reach the five-service cap, and research found a common midpoint appointment length of 40–44 minutes. The recommendations remain subject to finalisation, formal submission to government and consideration through the Budget process.
- 03
Low STI testing found among women prescribed opioid agonist therapy
Women with a history of opioid agonist therapy prescriptions had low testing uptake and substantial chlamydia and gonorrhoea positivity in Australian surveillance data. Among more than 6800 women aged 15–55, only one-third had a recorded test at participating services between 2012 and 2025; positivity among those tested was 4% for chlamydia and 3% for gonorrhoea. Positivity was around 7% overall among women aged under 30. Of those retested after an infection, 21% had another positive chlamydia result and 18% had another positive gonorrhoea result. Current Australian STI management guidelines suggest considering chlamydia and gonorrhoea testing in this population, while GP expert Associate Professor Marguerite Tracy identified stigma, discrimination, cost and access as significant barriers.
via RACGP newsGP
- 04
EMA opens reviews of Deanxit and human immunoglobulin safety signals
The EMA’s Pharmacovigilance Risk Assessment Committee has opened separate safety reviews of Deanxit and human normal immunoglobulin medicines. The Deanxit review followed reports of serious neurological and psychiatric effects, including movement disorders and memory and thinking problems, with some symptoms persisting after treatment stopped. The immunoglobulin review concerns higher-than-expected hypersensitivity reporting linked to specific batches, with reactions ranging from rash and itching to anaphylaxis and angioedema. Certain batches of Flebogamma DIF, Yimmugo and Gamunex have already been recalled in some EU member states, but the cause remains unknown and the review will cover all human normal immunoglobulin products and administration routes. The committee reminded healthcare professionals to follow existing product warnings and precautions, including monitoring patients during treatment.
- 05
Medline to discontinue beds after deaths and serious injuries
Medline brand beds were linked to two deaths and 16 serious injuries in an early alert published by the US Food and Drug Administration. Electrical components in the beds, hand control pendants, control boxes and motors may overheat under certain conditions, causing smoking, sparking, melting, burning or fire. Medline also received adverse event reports involving potential entrapment or asphyxiation associated with accessories, loose or wobbly rails, or patients lying on a pendant. The company plans to discontinue its beds and associated products and exit the market, while offering repairs for certain beds and possible replacements or refunds for eligible products bought in the past five years. Medline said affected devices could remain in use pending repair or replacement if users followed updated instructions, including plugging beds into outlets only when repositioning patients and, where possible, having a second person assist.
via MedTech Dive
- 06
More than 120,000 referrals disappeared from NHS electronic system
More than 120,000 specialist referrals, advice and guidance requests, and review referrals disappeared from England’s electronic referral service between February and July 2026. The Health Services Safety Investigations Body said the issue emerged only after GPs reported that patients had not heard from providers, raising the possibility that some referrals might otherwise have been missed. The watchdog found no evidence that patients were harmed, but acknowledged concerns that earlier specialist care might have allowed some patients to avoid invasive treatment. NHS England supplies the web-based system for referrals to specialist providers.
via BMJ
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.